Melanoma in 2013: Melanoma - The run of success continues

Nature Reviews Clinical Oncology

Volumn 11, Issue 2, 2014, Pages 75-76

  Schadendorf, Dirk ^a   Hauschild, Axel ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; SKIN NEOPLASMS; TIME FACTORS;

EID: 84895902523     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.246     Document Type: Review

References (10)

1. Eggermont, A. M., Spatz, A. & Robert, C. Cutaneous melanoma. Lancet http://dx.doi.org/10.1016/S0140-6736(13)60802-8.
2. Trunzer, K. et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31, 1767-1774 (2013).
3. Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255 (2013).
4. Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B (high) cells. Cancer Cell 23, 811-825 (2013).
5. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
6. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
7. Knight, D. A. et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123, 1371-1381 (2013).
8. Ribas, A. et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
9. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959-961 (2013).
10. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959 (2013).